Cubist Pharmaceuticals, Inc. Announces Third Quarter 2003 Earnings Conference Call.Business Editors LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 3, 2003 Cubist Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CBST CBST Center for Biophotonics Science and Technology CBST Congregation Beth Simcha Torah (NYC) CBST Complete Binary Search Tree ), will hold its third quarter earnings conference call on Wednesday, November 5, 2003, at 10:30 a.m. Eastern Time. Live Domestic & Canada Call-In: (800) 404-1354 Live International Call-In: (706) 643-0825 24-Hour Replay Domestic & Canada: (800) 642-1687 (#3654474) 24-Hour Replay International: (706) 645-9291 (#3654474) Replay will be available for 30 days via the Internet; a transcript of the call will be filed with the SEC and will also be available upon request This call is being webcast by CCBN CCBN Central Coast Bancorp CCBN Charles County Business Network and can be accessed at Cubist's web site at www.cubist.com. The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com). About Cubist Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of antiinfective drugs. Cubist recently received approval from the U.S. Food & Drug Administration to market Cubicin(TM) (daptomycin for injection), for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Cubist's pipeline includes CAB-175, a next- generation parenteral parenteral /pa·ren·ter·al/ (pah-ren´ter-al) not through the alimentary canal, but rather by injection through some other route, as subcutaneous, intramuscular, etc. par·en·ter·al adj. 1. cephalosporin cephalosporin (sĕf'əlōspôr`ĭn), any of a group of more than 20 antibiotics derived from species of fungi of the genus Cephalosporium and closely related chemically to penicillin. Cephalosporins, e.g. antibiotic in Phase 1 trials, and an oral version of ceftriaxone ceftriaxone /cef·tri·ax·one/ (cef?tri-ak´son) a semisynthetic, ß–resistant, third-generation cephalosporin effective against a wide range of gram-positive and gram-negative bacteria, used as the sodium salt. (OCTX), a broad-spectrum cephalosporin antibiotic in pre-clinical development. Cubist is headquartered in Lexington, MA. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion